Early changes in IL‐21, IL‐22, CCL2, and CCL4 serum cytokines after outpatient autologous transplantation for multiple sclerosis: A proof of concept study

2020 ◽  
Vol 34 (12) ◽  
Author(s):  
José C. Jaime‐Pérez ◽  
Grecia A. Turrubiates‐Hernández ◽  
Leslie J. López‐Silva ◽  
Rosario Salazar‐Riojas ◽  
David Gómez‐Almaguer
Keyword(s):  
Multiple Sclerosis ◽  
Autologous Transplantation ◽  
Proof Of Concept ◽  
Concept Study ◽  
Serum Cytokines

scholarly journals In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET

2018 ◽  
Vol 15 (1) ◽  
Author(s):  
Marloes H. J. Hagens ◽  
Sandeep V. Golla ◽  
Martijn T. Wijburg ◽  
Maqsood Yaqub ◽  
Dennis Heijtel ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Progressive Multiple Sclerosis ◽  
Proof Of Concept ◽  
Concept Study ◽  
In Vivo Assessment

scholarly journals A cell-based assay for the detection of neutralizing antibodies against alemtuzumab

BioTechniques ◽  
2020 ◽  
Vol 68 (4) ◽  
pp. 185-190 ◽  
Author(s):  
Liaqat Ali ◽  
Gauri Saxena ◽  
Meleri Jones ◽  
Georgia R Leisegang ◽  
Luke Gammon ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Monoclonal Antibody ◽  
Cell Surface ◽  
Cell Line ◽  
Neutralizing Antibodies ◽  
Proof Of Concept ◽  
Alexa Fluor ◽  
Concept Study ◽  
A Cell ◽  
Relapsing Multiple Sclerosis

Aim: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future treatment cycles. Results: Alemtuzumab–Alexa Fluor 488 conjugate binding to the CHO-CD52 cell surface was inhibited by anti-alemtuzumab antibodies. Conclusion: In this proof-of-concept study, a CHO-CD52 cell line has been developed and used to detect the presence of anti-alemtuzumab neutralizing antibodies. This platform provides the basis of an assay for routine screening of serum for neutralizing antibodies from patients treated with alemtuzumab.

scholarly journals Osteopathic Manipulative Therapy and Multiple Sclerosis: A Proof-of-Concept Study

2018 ◽  
Vol 118 (8) ◽  
pp. 531 ◽  
Author(s):  
Christian Cordano ◽  
Annalisa Armezzani ◽  
Jacopo Veroni ◽  
Matteo Pardini ◽  
Davide Sassos ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Proof Of Concept ◽  
Concept Study ◽  
Manipulative Therapy
Sign in / Sign up

Export Citation Format

Share Document